NCT00229333Unknown4 期
Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer's Disease, Vascular Dementia and Mixed Vascular and Alzheimer's Dementia
适应症
相关药物
试验速览
- 阶段
- 4 期
- 入组人数
- 40
- 试验地点
- 2
- 主要终点
- Cornell Scale for Depression in Dementia (CSDD) total score
研究概览
简要总结
The goal of the present study is to compare the effectiveness of the active (S)-enantiomer of citalopram, escitalopram with placebo in the treatment of patients with depressive syndrome complicating Alzheimer's dementia (AD), vascular dementia (VD) or mixed dementia (MD), for 8 weeks of double-blind treatment.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject meets criteria for the diagnosis of Alzheimer's dementia, or vascular dementia, or mixed alzheimer's and vascular dementia, according to Diagnostic and Statistical for Mental Disorders, Fourth Edition (DSM-IV) criteria.
- •Subject meets the following criteria for depressive syndrome: DSM-IV criteria for major depressive episode; and Cornell Scale of Depression in Dementia is 18 or more.
- •The depressive syndrome has been present for at least two weeks preceding study entry (Visit 1).
- •The depressive syndrome must be at least moderate in severity at Visit 1 and Visit 2 (cause the subject impairment in functional capacity) and in the opinion of the investigator require pharmacological intervention.
- •Score on the Mini Mental State Examination (MMSE) of 10-26 at Visit 1 and at Visit
- •Other possible reasons for the subject's depressive symptoms, for example, medications or other medical conditions (such as pain, infection, cancer of the pancreas, etc.), have been excluded as an etiology.
排除标准
- •General Exclusion Criteria:
- •Subjects who need placebo run-in period, and/or their caregivers are unable to comply with Study Period I medication to the extent that drug compliance in the remainder of the study would be compromised as determined by the investigator.
- •Investigators, site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse, parent, child or sibling, whether biological or legally adopted.
- •Diagnostic Exclusion Criteria:
- •Schizophrenia
- •Subjects who are judged clinically to be at serious suicidal risk at Visit
- •Subjects who have clinically significant psychotic symptoms at Visit
- •Subject has a serious neurological condition other than AD, VD or MD including, but not limited to: traumatic (head-brain) dementia, space-occupying lesion, relevant structural abnormalities on brain imaging, etc.
- •Subject who underwent CVA for 3 months.
- •Subject is doing well on a current antidepressant drug regimen.
- •Exclusionary Concurrent or Historical Illness:
- •Subjects with severe hepatic or renal insufficiency.
- •Hypo/hyperthyroidism
- •B-12 deficiency
- •Exclusionary Concomitant or Historical Medications:
- •Participation in a clinical trial of another investigational drug within 30 days prior to study entry (Visit 1) and/or any concurrent investigational study.
- •Subjects with a history of severe adverse reaction to citalopram or escitalopram.
- •Concomitant medication as specified.
- •Previous treatment with escitalopram unless, in the opinion of the investigator, the patient's previous treatment was inadequate in dose and/or duration to provide an accurate assessment of the therapy.
结局指标
主要结局
Cornell Scale for Depression in Dementia (CSDD) total score
次要结局
- Cohen-Mansfield Agitation Inventory (CMAI; Cohen-Mansfield et al. 1989)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Clinical Trial of Cilostazol Eluting Stent System (CES-1) in De Novo Coronary Artery LesionsCoronary Artery DiseaseNCT03189641JIMRO Co., Ltd.30
已完成
1 期
Pharmacodynamic Study of Cilostazol in Healthy VolunteersHealthyNCT02554721Otsuka Pharmaceutical Co., Ltd.77
终止
3 期
Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive EpisodeDepressionNCT02532660Laboratório Catarinense SA111
已完成
3 期
Trial of Citicoline Therapy in Patients With Mania or Hypomania and Cocaine Abuse/DependenceHypomaniaCocaine AbuseCocaine DependenceManiaNCT00223236University of Texas Southwestern Medical Center44
已完成
3 期
Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac SurgeryBleedingNCT02655653Montefiore Medical Center114